Fri, Aug 22, 2014, 3:26 PM EDT - U.S. Markets close in 34 mins.

Recent

% | $
Quotes you view appear here for quick access.

Highpower International, Inc. Message Board

siestacottage 22 posts  |  Last Activity: 1 hour 17 minutes ago Member since: Apr 3, 2003
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • siestacottage by siestacottage Jun 12, 2014 6:28 AM Flag

    Shorts are always bitter with their comments until the positive results come. Foolish wrap-up
    In light of the diversity of diseases Inovio is targeting with its platform and the blockbuster potential of a new HPV vaccine, it's easy to understand why investors remain optimistic about the company's future. If positive, Inovio could see one of the biggest short squeezes in biotech history.

  • If positive, Inovio could see one of the biggest short squeezes in biotech history. This comment is buried in The latest Fool article. This is what we have been waiting for, The mother of all short squeezes...

  • The following links also include publications related to other technology owned by the company.

    HPV/Cervical Dysplasia & Cancer
    Morrow MP, Yan J, Sardesai NY. Human papillomavirus therapeutic vaccines: targeting viral antigens as immunotherapy for precancerous disease and cancer. Expert Rev Vaccines. 2013 Mar;12(3):271-83. doi: 10.1586/erv.13.23.

    The mother of all short squeezes - What would this look like ?
    If positive, Inovio could see one of the biggest short squeezes in biotech history. This comment is buried in The latest Fool article. This is what we have been waiting for, The mother of all short squeezes...

  • siestacottage by siestacottage Jun 12, 2014 7:07 AM Flag

    BIG pharma is looking at this trail. This is going to be the biggest short squeeze. Who knows, perhaps Inovio's consistent immune responses in its cancer trials may be the future growth catalyst Merck is seeking to remain relevant in the oncology field.

  • siestacottage by siestacottage Jun 12, 2014 7:21 AM Flag

    dont forget the ROCHE connection. Roche acquired an exclusive license for Inovio’s DNA-based vaccines INO-5150 (targeting prostate cancer) and INO-1800 (targeting hepatitis B) as well as the use of Inovio’s CELLECTRA® electroporation technology for delivery of the vaccines. Roche also obtained an option to license additional vaccine opportunities in connection with a collaborative research program in oncology. Roche and Inovio will collaborate to further develop INO-5150 and INO-1800.

  • When push comes to shove, what's going to matter most is VGX-3100's mid-stage results that are set to be released at anytime. If positive, Inovio could see one of the biggest short squeezes in biotech history. So all eyes are closely watching the company's mid-stage DNA vaccine dubbed "VGX-3100," which is expected to report top-line data at any time now. In light of the diversity of diseases Inovio is targeting with its platform and the blockbuster potential of a new HPV vaccine, it's easy to understand why investors remain optimistic about the company's future. When push comes to shove, what's going to matter most is VGX-3100's mid-stage results that are set to be released at anytime. ANYTIME !!! be ready

  • siestacottage siestacottage Jun 12, 2014 7:54 AM Flag

    I looked at his past articles, he is getting paid off someplace. The stocks he hates get slammed but recover after a few weeks. And the stock that he loves are main stream pharma. He hates all micro stocks, always has negative comments, even if they move up nicely over time. he protects big Pharma.

  • siestacottage by siestacottage Jun 12, 2014 7:58 AM Flag

    Roche and Inovio Pharmaceuticals partner on Inovio's prostate cancer and hepatitis B immunotherapy products

    and the money is rolling in from this partnership.

  • Investors in Inovio Pharmaceuticals Inc. (INO_) saw new options become available this week, for the June 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the INO options chain for the new June 21st contracts and identified the following put contract of particular interest.

    The put contract at the $2.50 strike price has a current bid of 35 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $2.50, but will also collect the premium, putting the cost basis of the shares at $2.15 (before broker commissions). To an investor already interested in purchasing shares of INO, that could represent an attractive alternative to paying $2.70/share today.

    Because the $2.50 strike represents an approximate 7% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 67%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 14.00% return on the cash commitment, or 85.17% annualized — at Stock Options Channel we call this the YieldBoost.

  • siestacottage by siestacottage Jun 12, 2014 8:27 AM Flag

    INO was is listed with 3.74 % positive pre market open ... http://thestockmarketwatch.com/markets/pre-market/today.aspx

  • Very Effective Response

    In its Phase-I trial of VGX-3100, INO demonstrated that the immunotherapy produced very high-levels of durable T-cell immune responses, very notably the CD8+ “killer” T cells, in 78 percent of all the patients in this study.
    June 12, 2014 Steven Gray

    Denver, CO, 06/12/2014 (Stocksntrade) – Inovio Pharmaceuticals Inc (NYSEMKT:INO) recently announced that the company has initiated its phase I/IIA clinical-trial to evaluate the safety, immunogenicity & clinical responses of INO-3112,- the immunotherapy product, in the treatment of human papillomavirus- associated head & neck cancer. This drug is a mix of VGX-3100, , INO’s lead active-immunotherapy product, & 12 (IL-12), its proprietary immune-activator expressing interleukin, VGX-3100 is now being evaluated in the randomized Phase-II efficacy-trial for treatment of the high-grade cervical dysplasia.

    Very Effective Response

    In its Phase-I trial of VGX-3100, INO demonstrated that the immunotherapy produced very high-levels of durable T-cell immune responses, very notably the CD8+ “killer” T cells, in 78 percent of all the patients in this study. The CD8+ T cells indicated functional ability to effectively kill the target cells that display the E6 & E7 antigens. In the preclinical animal-models, Inovio Pharmaceuticals Inc (NYSEMKT:INO)’s HPV immunotherapy demonstrated 100 percent protection against the HPV E6 & E7-expressing tumors & prevented/ delayed growth of those tumors. This proprietary IL-12 immune activator- INO-9012 had earlier indicated that it could enhance antigen-specific CD4+ & CD8+ T-cell immune responses to INO’s PENNVAX® HIV-DNA vaccine in its clinical trial.

    The Nest Phases

    Inclusion of the DNA-based immune-activator in INO-3112 is specifically designed to increase generation of the HPV-specific CD8+ T cells for treatment of the HPV-related cancer. In the open-label study, that is named HPV-005, upto 20 adults suffering from HPV-positive head & neck squamous cell carc

  • siestacottage by siestacottage Jun 12, 2014 8:43 AM Flag

    Denver, CO, 06/12/2014 (Stocksntrade) – Inovio Pharmaceuticals Inc (NYSEMKT:INO) recently announced that the company has initiated its phase I/IIA clinical-trial to evaluate the safety, immunogenicity & clinical responses of INO-3112,- the immunotherapy product, in the treatment of human papillomavirus- associated head & neck cancer. This drug is a mix of VGX-3100, , INO’s lead active-immunotherapy product, & 12 (IL-12), its proprietary immune-activator expressing interleukin, VGX-3100 is now being evaluated in the randomized Phase-II efficacy-trial for treatment of the high-grade cervical dysplasia.

    Very Effective Response

    In its Phase-I trial of VGX-3100, INO demonstrated that the immunotherapy produced very high-levels of durable T-cell immune responses, very notably the CD8+ “killer” T cells, in 78 percent of all the patients in this study. The CD8+ T cells indicated functional ability to effectively kill the target cells that display the E6 & E7 antigens. In the preclinical animal-models, Inovio Pharmaceuticals Inc (NYSEMKT:INO)’s HPV immunotherapy demonstrated 100 percent protection against the HPV E6 & E7-expressing tumors & prevented/ delayed growth of those tumors. This proprietary IL-12 immune activator- INO-9012 had earlier indicated that it could enhance antigen-specific CD4+ & CD8+ T-cell immune responses to INO’s PENNVAX® HIV-DNA vaccine in its clinical trial.

    The Nest Phases

    Inclusion of the DNA-based immune-activator in INO-3112 is specifically designed to increase generation of the HPV-specific CD8+ T cells for treatment of the HPV-related cancer. In the open-label study, that is named HPV-005, upto 20 adults suffering from HPV-positive head & neck squamous cell carcinoma will be treated with the company’s INO-3112. They will be followed for safety, immune & the clinical responses. In 1 segment part of this study, upto 10 patients will be treated with the INO-3112 before & after resection of the tumor. In the 2nd pa

  • Merck, Roche and BMY have created a monoclonal antibody, called a checkpoint inhibitor, which allows T-cells to recognize and kill cancer cells. This passive cancer approach is a great validation of the importance of T-cells in immunotherapy as T-cells and only T-cells are essential in killing cancer cells.

  • siestacottage by siestacottage Jun 12, 2014 9:24 AM Flag

    Denver, CO, 06/12/2014 (Stocksntrade) – Inovio Pharmaceuticals Inc (NYSEMKT:INO) recently announced that the company has initiated its phase I/IIA clinical-trial to evaluate the safety, immunogenicity & clinical responses of INO-3112,- the immunotherapy product, in the treatment of human papillomavirus- associated head & neck cancer. This drug is a mix of VGX-3100, , INO’s lead active-immunotherapy product, & 12 (IL-12), its proprietary immune-activator expressing interleukin, VGX-3100 is now being evaluated in the randomized Phase-II efficacy-trial for treatment of the high-grade cervical dysplasia.

    Very Effective Response

    In its Phase-I trial of VGX-3100, INO demonstrated that the immunotherapy produced very high-levels of durable T-cell immune responses, very notably the CD8+ “killer” T cells, in 78 percent of all the patients in this study. The CD8+ T cells indicated functional ability to effectively kill the target cells that display the E6 & E7 antigens. In the preclinical animal-models, Inovio Pharmaceuticals Inc (NYSEMKT:INO)’s HPV immunotherapy demonstrated 100 percent protection against the HPV E6 & E7-expressing tumors & prevented/ delayed growth of those tumors. This proprietary IL-12 immune activator- INO-9012 had earlier indicated that it could enhance antigen-specific CD4+ & CD8+ T-cell immune responses to INO’s PENNVAX® HIV-DNA vaccine in its clinical trial.

    The Nest Phases

    Inclusion of the DNA-based immune-activator in INO-3112 is specifically designed to increase generation of the HPV-specific CD8+ T cells for treatment of the HPV-related cancer. In the open-label study, that is named HPV-005, upto 20 adults suffering from HPV-positive head & neck squamous cell carcinoma will be treated with the company’s INO-3112. They will be followed for safety, immune & the clinical responses. In 1 segment part of this study, upto 10 patients will be treated with the INO-3112 before & after resection of the tumor. In the 2nd pa Less

  • siestacottage by siestacottage Jun 12, 2014 10:19 AM Flag

    ON the move today

  • were you able to get out? at what price.

  • siestacottage by siestacottage Jul 18, 2014 11:29 AM Flag

    buyout is coming, load up.

  • siestacottage by siestacottage Jul 31, 2014 11:28 AM Flag

    Not today ?

  • siestacottage by siestacottage Aug 14, 2014 7:42 AM Flag

    looks good with earnings

  • siestacottage by siestacottage Aug 20, 2014 9:07 AM Flag

    HPJ with great earnings, a new contract, and PE of 55, this stock is valued at $7 -$9 ... it should hit $7.50 today.

HPJ
5.317+0.167(+3.24%)3:23 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.